Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

icipated global demand for Myozyme. Product supply in 2009 is expected to be particularly tight until the Belgium plant is approved.

Genzyme's other treatments for lysosomal storage disorders also continue to experience strong, double-digit growth. Second-quarter Cerezyme(R) (imiglucerase for injection) sales rose 13 percent to $319.4 million, compared with $283.0 million in the previous second quarter. Sales of Fabrazyme(R) (agalsidase beta) grew 21 percent, rising to $126.6 million from $104.3 million. Sales of Aldurazyme(R) (laronidase) increased 33 percent to $38.8 million, compared with $29.1 million in the second quarter last year when the product's sales were recorded under the joint venture with BioMarin Pharmaceutical Inc.

The company also reported preliminary results from a Phase 2 trial of its investigational oral therapy for Gaucher disease Genz-112638. The results were consistent with those observed for patients beginning enzyme replacement therapy, and they highlight the potential of this compound to provide a convenient treatment alternative for patients and a broader range of treatment options for physicians. Genzyme is developing protocols for two Phase 3 trials that it expects to initiate early next year.

Sales of Thyrogen(R) (thyrotropin alfa for injection) remained strong, increasing 34 percent to $39.4 million from $29.5 million. The use of Thyrogen in ablation procedures is contributing to the product's growth in the United States, while its growth in Europe is being driven by increasing diagnosis of thyroid cancer and its international adoption is being driven by expansion into new geographic markets.

Within the Renal business, sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela grew 16 percent to $168.6 million from $144.9 million in the second quarter last year. Genzyme launched Renvela in the United States in March, and the product is now included in more than 85 percent of health plan f
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 iLuv Creative ... of accessories for the mobile lifestyle, announces they are ... protect, and manage multiple iPad devices efficiently. Winner of ... the 2012 Good Design award, MultiCharger-X is revolutionizing the ... wherever it is deployed. , MultiCharger-X (iAD910) ...
(Date:5/22/2013)... 22, 2013   Oligomerix, Inc. , a ... modifying therapeutics for Alzheimer,s disease (AD) and related ... Series B financing, which includes both issuance of ... represent approximately $2.8M in new investments in the ... the raise. Funding from the ...
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013  Organogenesis ... medicine, presented new data generated in collaboration with a ... health economics consultancy) demonstrating the significant healthcare resource and ... leg ulcers (VLU) place upon the US healthcare system. ... reveal annual costs of up to $15 billion and ...
(Date:5/22/2013)... 22, 2013 AudioNotch ... for tinnitus treatment. AudioNotch is pleased to announce ... clinic locations in both British Columbia and Alberta, ... and hearing services. AudioNotch's tinnitus treatment program is ... entering a Destination Hearing clinic, patients have the ...
Breaking Biology Technology:iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2
... hold the key to production of tiny medical ... viruses or cancer markers, according to an interdisciplinary ... can be made more useful by assembling, at ... nanowires pretreated off chip," says Rustom B. Bhiladvala, ...
... 7 Eli Lilly and Company,(NYSE: LLY ) ... program, which was being conducted in partnership with Alkermes,Inc. ... as a potential,treatment for type 1 and type 2 ... result of any observations during AIR Insulin trials,relating to ...
... 7 Kendle (Nasdaq: KNDL ), a,leading, ... Chief Executive Officer Candace Kendle, PharmD, and,President and ... plans to sell shares of the company,s common ... are part of their personal,ongoing long-term strategy for ...
Cached Biology Technology:Assembly technique for tiny wires may eventually help detect cancer and other diseases 2Assembly technique for tiny wires may eventually help detect cancer and other diseases 3Lilly Announces Termination of AIR Insulin Program 2Lilly Announces Termination of AIR Insulin Program 3Lilly Announces Termination of AIR Insulin Program 4Kendle Leaders Adopt 10b5-1 Trading Plans 2
(Date:5/21/2013)... a "patient monitoring" device attached to a whale entangled ... how fishing lines changed a whale,s diving and swimming ... ability to eat and migrate, depletes their energy as ... result in a slow death. , The scientists in ... Dtag to a two-year-old female North Atlantic right whale ...
(Date:5/21/2013)... stem cells in the blood often jump into ... cells that can fight off illness. But repeated ... potentially leading to the development of serious blood ... researchers led by biologists at the California Institute ... models, the molecule microRNA-146a (miR-146a) acts as a ...
(Date:5/21/2013)... Cancers of all types become most deadly when they ... has reached this stage, it becomes very difficult for ... can develop. Now, researchers at the University of Missouri ... target lymphoma tumor cells wherever they may be in ... in the MU College of Veterinary Medicine, says being ...
Breaking Biology News(10 mins):Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3Keeping stem cells strong 2MU researchers develop radioactive nanoparticles that target cancer cells 2
... Elsevier, a world-leading provider of scientific, technical and medical ... Dietetics announce that the Journal of the American Dietetic ... of Nutrition and Dietetics , mirroring the name change of ... "The new name, the Academy of Nutrition and Dietetics, ...
... of increasing concern about low vitamin D levels in the ... vitamin, scientists are reporting development of a much-needed reference material ... The report appears in ACS, journal Analytical Chemistry . ... vitamin D deficiency or insufficiency may be even more common ...
... The research assesses the benefits of white roofs and aims ... white roofs are suitable for their buildings and guide them ... Robert Doyle said Council had already put the research into ... "There has been a lot of talk about ...
Cached Biology News:Journal of American Dietetic Association becomes Journal of the Academy of Nutrition and Dietetics 2New standard for vitamin D testing to ensure accurate test results 2White roofs to make for cooler Melbourne buildings 2
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
...
Request Info...
Biology Products: